Key Highlights
● Heron received an exclusive, sublicensable US license from Long Grove Pharmaceuticals to import, distribute, sell and market certain products.
● Heron also holds a non-exclusive worldwide license to manufacture the products for sale in the United States and its territories.
● The agreement includes regulatory milestones, sales-based milestones and royalties, with an initial term of ten years after first commercial sale.
● Capstone is a party solely for exclusivity covenants and backstop obligations, and Heron will file the agreement with its 10-Q.
Heron Therapeutics, Inc. (NASDAQ:HRTX) disclosed in a Form 8-K that it entered into a license agreement with Long Grove Pharmaceuticals, LLC, effective September 23, 2026, giving Heron an exclusive, sublicensable license in the United States to import, distribute, sell and market certain products. Capstone Development Services Company, LLC is also a party, solely to provide exclusivity covenants and backstop obligations. The company reported the agreement under Item 1.01 and said it will file the full agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The 8-K was signed on September 29, 2026 by Ira Duarte, Executive Vice President and Chief Financial Officer.
The License Terms
The parties are Heron, a Delaware corporation; Long Grove Pharmaceuticals, LLC, a Delaware Limited Liability company, which grants the license; and Capstone Development Services Company, LLC. The territory is the United States, including its territories, commonwealths and possessions. Heron receives an exclusive license, which it may sublicense, to import, distribute, sell and market the products in that territory. It also receives a non-exclusive license to manufacture the products worldwide, for the purpose of sales in the territory.
The filing does not name the products, and no product names appear in the text of the report. It says only that they are certain products covered by the agreement, so the therapeutic area, the regulatory status and the size of the potential market are not disclosed in the filing.
Payments, Duration and Capstone's Role
The agreement provides for regulatory milestone payments, sales-based milestone payments and Royalty payments. The filing does not disclose the amounts, the royalty rate or any upfront payment, and it does not say which party pays which. The initial term is ten years following the first commercial sale, with automatic renewal terms of two years each. Either party may terminate on the occurrence of certain conditions the filing describes as customary for agreements of this type.
Because the term is measured from first commercial sale, the summary in the 8-K does not set a date on which sales must begin. The 8-K does not say when Heron expects any regulatory milestones to occur or when it expects to begin selling, and it does not describe what regulatory steps, if any, are required before commercialization.
The filing states that Capstone Development Services Company, LLC is a party to the license agreement solely to provide certain exclusivity covenants and backstop obligations. It does not define those obligations.
Why the Filing Was Made
Item 1.01 of Form 8-K requires a registrant to report the entry into a material definitive agreement that is not in the ordinary course of business, with a brief description of the date, the parties and the material terms. Heron treated the license as falling within that item. The filing does not include risk-factor language, financial projections or a statement about the agreement's expected effect on Heron's Revenue or expenses.
Heron's Long Grove License and the 10-Q Exhibit
The key disclosure to look for is the Form 10-Q for the quarter ending September 30, 2026, to which Heron says it will attach the full license agreement. That exhibit should contain the definitions of the products, the milestone events, the royalty structure and the termination provisions. What the license means for Heron's other commercial products, whether any portions of the exhibit will be redacted, and when the products might become available are not stated in the 8-K.






Please wait processing your request...